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Abstract  
Background: The efficacy of adjunctive psychosocial interventions such as Cognitive 
Behaviour Therapy (CBT) for Bipolar Disorder (BD) has been shown in several uncontrolled 
and controlled studies. However all of these studies compared CBT to either a waiting list 
control group, brief psychoeducation or treatment-as-usual. The primary goal was to examine if 
CBT is superior to Supportive Therapy (ST) of equal intensity and frequency in preventing 
relapse and improving outcome at post-treatment. A secondary goal was to look at predictors of 
survival time.  
Methods: We conducted a randomized controlled trial in Germany at the outpatient clinic of a 
Psychological Institute (n = 76 patients with BD). Both CBT and ST consisted of 20 sessions 
within 9 months. Patients were followed up for a further 24 months.  
Results: Although changes over time were observed in some variables, they were not 
differentially associated with CBT or ST. CBT showed a non-significant trend for preventing 
any affective, specifically depressive episode during the time of therapy. Kaplan Meier survival 
analyses revealed that 64.5% of patients experienced a relapse during the 33 months. Number of 
prior episodes, number of therapy sessions and type of BD predicted survival time. 
Conclusions: No differences in relapse rates between treatment conditions were observed, 
suggesting that certain shared characteristics (e.g. information, systematic mood monitoring) 
might explain the effects of psychosocial treatment for bipolar disorder. Our results additionally 
suggest that a higher number of prior episodes, a lower number of therapy sessions and a 
diagnosis of bipolar-II-disorder are associated with shorter time before relapse.   
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Bipolar disorders (BD) are more frequent and disabling than originally thought with many 
patients showing significant impairment or subsyndromal symptoms between episodes (e.g. 
Judd & Akiskal, 2003; Judd et al., 2002; Solomon et al., 2010). Although medication is needed, 
the role of psychosocial factors for onset and course of BD has become obvious (e.g. Alloy et 
al., 2005; Johnson, 2005) and led to the development of several psychosocial interventions. 
Cognitive Behaviour Therapy (CBT) relies on the assumption that the interaction of 
thoughts, behaviours and emotions is underlying psychopathology, including depression and 
mania. Indeed empirical evidence has demonstrated the role of cognitive vulnerability factors 
such as dysfunctional attitudes or attributional style for BD and mania (e.g. Alloy et al., 2009; 
Johnson, 2005; Jones et al., 2005), Several reviews have been published looking at the efficacy 
of psychotherapy for BD (e.g. Beynon et al., 2009; Miklowitz & Scott, 2009; Szentagotai & 
David, 2010), and briefly summarized indicate that CBT for BD works better than waiting for 
treatment (Scott et al., 2001), is more beneficial than  brief psychoeducation (Zaretsky et al., 
2008) and mostly proved to be superior to treatment-as-usual (TAU) with respect to functioning 
and relapse prevention (e.g. Ball et al., 2006; Lam et al., 2003). Focusing on overall relapse 
rates from four RCTs in their meta-analysis, Lynch et al. (2010) conclude that CBT is not 
effective for BD. Indeed Scott et al. (2006) did not find an overall effect for CBT with regard to 
relapse prevention for severe BD but individuals with fewer episodes benefitted from receiving 
CBT. Despite these encouraging results, there are limitations, for example the amount of 
attention patients in the control groups received has not been controlled. For example, waiting 
for treatment has its own negative effects with 30% of patients dropping out (Scott et al., 2001). 
TAU, on the other hand, mostly included regular visits to the psychiatrist, and crises 
management. This was usually provided to all study participants, so that in effect CBT was 
actually an add-on intervention. Therefore, the patients treated with CBT received much more 
attention and support of any kind compared to those in the control conditions. This renders 
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interpretations ambiguous (e.g. Goldfried & Wolfe, 1998). The primary goal of our study 
therefore was to examine if the positive results with regard to relapse rates and post-treatment 
improvements in former studies are still evident if people are randomized to CBT or another 
treatment condition that is matched in frequency and intensity of contact (i.e. ‘supportive 
therapy’). We used relapse rates as the main outcome variable but also considered symptom 
levels and indicators of cognitive vulnerability (e.g. locus of control). It was expected that CBT 
would lead to lower relapse rates, decrease symptoms levels and cognitive vulnerability (e.g. 
increased internal locus of control). A secondary goal was to test whether illness related 
variables which have been identified in other studies predict survival time, specifically length of 
treatment, number of prior episodes, age of onset, medication, psychosocial functioning and 
type  of BD (e.g. Zaretsky et al., 2008; Miklowitz et al., 2003; Scott et al., 2006, 2007).  
Method 
Participants. Recruitment took place in the Department of Psychology, University of 
Tübingen, Germany, between August 1999 and September 2004. The patients were either 
referred by local hospitals, psychiatrists or were self-referrals due to public information in 
newspapers or on radio. Participants were invited to a screening session in which they were 
informed about the study and gave written informed consent. Baseline assessment consisted of 
at least three consecutive sessions, in which clinical interviews (e.g. Structured Clinical 
Interview for DSM-IV axis I and II) and self-ratings (e.g. BDI) were completed.  
The inclusion criteria for the study were a) a primary disorder of BD according to DSM-IV 
(APA, 1994), b) age between 18 and 65 years, and c) willingness to continue current or start 
medication.  Exclusion criteria were: a) the primary diagnosis is a non-affective disorder 
including schizoaffective disorder, b) current major affective episode (depressed, mixed or 
mania according to SCID-I) or Bech Rafaelsen Melancholia Scale > 14 or Bech Rafaelsen 
Mania Scale > 9, c) affective disorder substance-induced or due to a general medical condition, 
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d) current substance dependency requiring detoxification [abuse did not qualify for exclusion], 
e) serious cognitive deficits (IQ < 80), f) being currently in psychological treatment. 
Treatment conditions: Patients were randomly allocated to individual CBT or ST using a 
stratified randomization strategy controlling for gender, bipolar I or II disorder, and age of onset 
(before/ after age of 20). Treatment started within 2-4 weeks after the assessments. Both 
treatments consisted of 20 sessions (50 to 60 minutes) distributed over nine months. The first 12 
sessions were provided on a weekly basis, then bi-weekly sessions were offered for the next two 
months and the remaining sessions were scheduled monthly. Manuals were provided for both 
treatments with the CBT one being published (Meyer & Hautzinger, 2004). Both treatment 
conditions included information (e.g. symptoms, aetiology, medication) and mood monitoring in 
the form of a mood diary. The difference between therapies was such that in the ST condition 
therapists adopted a client-centered focus meaning that whatever problems the patient presented 
were dealt with by providing emotional support and general advise. If no specific topic was 
mentioned by the patient, information about BD and medication was delivered by the therapist 
without referring to written or any other materials. In contrast to the CBT no efforts were made 
to specifically link this information to the individuals’ biography or experience. The mood diary 
was checked by the therapist who provided brief feedback (e.g. regularity of medication, of 
sleep and overall mood) or probed for missing information but without using any CBT-related 
techniques such as guided discovery, problem solving or reality testing,  
CBT covered a) an information and motivation module (providing and jointly elaborating 
information and an understanding of bipolar disorder, its symptoms, aetiology, course, triggers, 
and pharmacotherapy based and linked to the individual’s experience, but also addressing for 
example in this context potentially dysfunctional beliefs about bipolar disorder and medication), 
b) an individual relapse module (including life chart analysis, identification and monitoring of 
individual early warning symptoms for mania and depression, functional behaviour analysis or 
risky behaviours, coping with prodromal symptoms), c) Cognitive and behavioural strategies 
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dealing with depression and mania (e.g. cognitive restructuring, activity schedule/daily routine, 
planning pleasurable activities), and d) training of communication skills and/or problem solving 
skills depending on the individuals strengths and deficits. 
Therapists (n = 8, one being the first author) had a least one-year postgraduate training in 
CBT and had attended a specific 2-day workshop about CBT and ST for BD with role plays and 
video training. All therapy sessions were video-taped and weekly supervision was provided. 
 
Materials and Procedures: 
The Structured Clinical Interview for DSM-IV Axis I and II (SCID, First et al., 1996) was 
used by trained clinical psychologists to diagnose mental health problems at baseline and in the 
follow-up period. All interviews were videotaped, and a random sample of 53 patients was used 
to estimate reliability, which proved to be excellent (k = .93 for bipolar I, k = .89 for bipolar II). 
Relapse was defined as any mood episode which fulfilled DSM-IV criteria. Throughout the 
therapy period recordings were made of hospitalizations and episodes obtained by the 
clinicians’s notes and from the patients’ mood diaries (including also weekly CES-D 
assessments (Radloff, 1977: Hautzinger & Meyer, 2003). Severity of symptoms and functioning 
was also repeatedly assessed throughout the study period using the BRMS, BRMAS and Global 
Assessment Scale (GAS)(with good reliability (ICC = .87, .77 and .81 respectively). In addition 
several self-rating measures were used such as the Beck Depression Inventory (BDI, Beck & 
Steer, 1987; α=.89), the Self Rating Mania Inventory (SRMI, Shugar et al., 1992; α=.94). 
Furthermore the Locus of control for health and illness (LC; Lohaus & Schmitt, 1989) and 
Disease concept scale (‘Krankheitskonzeptskala’ [KK]; Linden et al., 1988) was used. The  21 
items of the LC are rated on a scale from ‘1’ totally true to ‘6’ not at all true and 3 composite 
scores can be calculated, i.e. internal locus of control (α=.89), external locus of control – 
powerful others (α=.76), and external locus of control – chance (α=.88). The KK is so far the 
only existing German scale that has been evaluated to assess subjective illness concepts of 
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patients. All 29 items are rated on a 5-point scale (‘0’ do not agree at all’ to ‘4’totally agree’). 7 
subscales were derived through factor analysis: trust in medication, trust in psychiatrist, negative 
expectations, guilt, chance, vulnerability, and idiosyncratic assumptions ( .67 [chance] < α < .85 
[trust in medication]). The LC and KK scales were assumed to be psychological concepts related 
to adherence and to reflemct effects of psychotherapy. To estimate adherence to medication the 
Somatotherapy Index (Bauer, 2001) was used. The best available data is used (mostly blood 
serum levels) to ensure the most accurate reporting of the maximum level of somatotherapy 
across medication types (i.e. ‘0’ no or very low levels of medication; ‘4’ indicating optimal 
pharmacotherapy). Cognitive testing was undertaken to ensure that intellectual functioning was 
sufficient (Leistungsprüfsystem, Horn, 1983). 
After baseline assessment (t0) participants were randomly assigned to CBT or  ST. 
Immediately following treatment the post-treatment assessment (t1) took place with raters who 
were blind to the treatment conditions. Further follow-up assessments took place every three 
months for the first year and one more after 2 years. The analysis reported here will focus on 
immediate effects of CBT on symptoms and psychological variables comparing pre- (t0) and 
post-treatment assessment (t1) as well as relapse rates for the total 33 month period. 
Statistical analysis: In the original planning stage a power analysis assuming a large effect 
size (with power = .80, p < .05) suggested a required sample size of 2 x 20 patients to detect 
mean differences and 2 x 26 for detecting differences in χ2-tests (Cohen, 1988). According to 
Chambless and Hollon (1998) such a sample size should reveal differences to be clinically 
meaning.  
Baseline comparisons were done if appropriate parametrically using t-tests for dimensional 
measures and used χ2 for categorical variables. All main analyses are presented as intend-to-treat 
analyses. Using SPSS 17.0 treatment effects were analysed with analysis of variance with 
repeated measurements including the factors time, treatment condition and their interaction. For 
the analyses, exact p-values will be reported up to p = .15. The primary hypothesis referring to 
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survival time (in weeks) was analyzed using Kaplan Meier curves with significance tests based 
on the log rank test. The secondary hypothesis was tested by running Cox proportional 
regressions to estimate the effects of the specified covariates for the whole sample including 
therapy condition: number of prior episodes, diagnosis (coded as ‘1’ bipolar I, ‘2’ bipolar II) age 
of onset, medication adherence (Somatotherapy index, 0 to 4), number of therapy sessions, and 
baseline overall functioning (GAS). Skew, kurtosis and univariate outliers were checked, and 
‘number of episodes’ was transformed using the natural logarithm (ln). No transformation 
improved skew of ‘number of therapy sessions’ so the original raw scores were used. Two 
multivariate outliers were identified (both men in their sixties with a comorbid personality 
disorder, one CBT/one ST) but since their inclusion did not change the results, they were 
included in the analyses. Analyses were conducted separately for any new affective episode, as 
well as for depressive and manic episodes (including hypomanic and mixed episodes).  
Results 
Patient characteristics 
Overall 141 patients contacted us (Figure 1). In some cases the only contact was via phone, 
Twenty individuals did not have a primary BD. Two patients were excluded because they had a 
current substance dependency. Nine patients withdrew their informed consent prior to start of 
treatment (mainly because of the required video taping of the therapy sessions). Comparing the 
randomized patients to the non-participating ones revealed no differences with respect to gender, 
type  of BD, lifetime diagnosis of alcohol- or substance related disorders, personality or anxiety 
disorders, all χ2 or Fishers’s exact tests p>.10, The same was true for age, age of onset, current 
medication adherence or current level of depression, all t<│1.15│. Patients who participated 
had low but significantly higher manic ratings (BRMAS), than those who discontinued, 
t(77.76)=2.73, p<.008, d=.41, M=1.68 [SD=3.22] vs. 0.50 [SD=0.86] respectively. Despite their 
higher subsyndromal manic symptoms, their current psychosocial functioning was considered 
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significantly higher than those who did not continue with the study, t(90) =2.10, p<.05, d=.58, 
M=69.59 [SD=12.64] vs. 62.31 [SD=12.45] respectively.  
Fifty-three (69.7%) out of the 76 patients had at least one mood stabilizer (and in 17 cases 
this was accompanied by an antidepressant medication). Seven (9.2%) were only on 
antidepressant medication, and16 (21.1%) did not take any medication at the beginning of the 
study. Of the 53 receiving mood stabilizers, the majority (51.3%, n = 39) had one, 13 (17.1%) 
had a combination of two and one individual (1.3%) three mood stabilizers (Lithium: n = 30; 
valproate: n = 16; carbamazepine: n = 9; antipsychotics: n = 13). The groups did not differ in the 
whether they had a mood stabilizer or antidepressant medication, all χ2≤ 1.27, n.s. (data not 
shown).   
In Table 1 the baseline characteristics of the final sample are displayed. No significant 
baseline differences between CBT and ST were found for any of the variables suggesting 
successful randomisation. Completers were those patients who attended at least 16 out of 20 
sessions. A total of 11 patients attended less than 16 sessions and were considered dropouts 
(14.5%). Most patients dropped out (82%) before session 10. Dropping out was unrelated to 
treatment condition, sex, marital status, type of BD or comorbid substance-use or anxiety 
disorders, all χ2≤ 1.81 or Fisher’s exact test p>.15. The same was true for age, current symptoms 
of depression, number of episodes, or psychosocial functioning according to the GAS, all 
t<1.58.  Dropouts were more likely to have a personality disorder diagnosis (54.5%) than 
completers (13.8%) (Fisher´s p=.006). When excluding dropouts, the average number of  
sessions attended was 18.53 (SD=1.09) for CBT and 19.28 (SD=1.17) for ST.  
Primary outcomes: post-treatment effects and relapse rates:  
Post-treatment effects: Descriptive data are displayed for baseline and post-treatment 
symptoms and indicators for psychosocial functioning in Table 2. As can be seen symptoms of 
depression significantly decreased over time, but there was no significant time x treatment 
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interactions for self-ratings or observer-ratings. Self-rated but not clinician-rated manic 
symptoms significantly decreased over time. Psychosocial functioning (GAS) improved, but this 
was not specific to either treatment condition. Using the Somatotherapy Index to quantify 
current medication adherence based on blood levels of different medications, there was no 
evidence for any change.  
Internal locus of control significantly increased over time, and external locus of control 
(chance) decreased but no significant time x treatment interaction was observed. Internal locus 
of control (powerful others) did not change over time. Some of the illness-related cognitions 
(e.g. negative expectations, idiosyncratic assumptions) changed over time in the expected 
direction, but no significant effect was found favouring CBT. There was only a non-significant 
trend for CBT-treated patients to trust their clinicians more after therapy.  
Relapse rates: Overall 64.5% (n=49) of the patients had at least one recurrence within the 33 
study months (see Table 1). On average the first recurrence occurred 67.53 (SE=9.21) after 
treatment for the CBT group and 66.25 weeks (SE=10.58) for the ST group. Kaplan Meier 
analyses revealed that survival times until  first recurrence of any affective episode did not 
significantly differ between therapy conditions, Log Rank (Mantel-Cox) χ2=0.004, n.s. (Figure 
2). Looking at first depressive recurrence, the mean survival times were 86.05 (SE=9.75) and 
88.86 (SE=11.15) for CBT and ST respectively, Log Rank χ2 =0.02, n.s. The equivalent survival 
times for any hypomanic, manic or mixed episode were 95.85 (SE=10.05) and 113.60 
(SE=0.97), again revealing no significant difference in survival time, Log Rank χ2=1.33, n.s. 
Secondary outcomes: predictors of survival time: 
Proportionality of hazards was tested and was given for all but ‘number of prior episodes 
(ln)’ so that its interaction with time was included in the analysis. The results of the Cox 
regression model are displayed in Table 3. Confirming the prior analysis, there was no 
statistically significant effect of therapy condition after adjusting for the seven covariates, -2 
Log Likelihood χ2(df=1)=0.11, p=.75, R2=.001, Survival time till any mood episode was, 
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however, predicted by the set of covariates, Log Likelihood χ2(df=7)=20.12, p<.005, R2=.23, 
with three predictors being significant and not including 1.00 in the C.I.. Patients with bipolar-I-
disorder had a 60% decrease in risk for a recurrence compared to bipolar-II-patients.  
Examination of the logarithm of the number of episodes each increase of one point increased 
risk for relapse by 7 %. However, risk for a relapse decreased by 10% with each therapy session. 
Analysis of survival time until first depressive episode, indicates that again the covariates 
contributed significantly to the prediction, Log Likelihood χ2(df=7)=20.68, p<.005, R2=.24, with 
bipolar-I versus -II and number of therapy sessions being significant predictors. More therapy 
sessions were again associated with longer time until depressive episode, and bipolar-II was 
associated with increased risk for depressive relapse.  A different picture emerged for manic-like 
episodes. Although number of prior episodes emerged as significant predictor of shortened 
survival time, overall the set of covariates did not significantly predict survival time, Log 
Likelihood χ2(df=7)=8.11, n.s., R2=.10 (Table 3),  
 
Discussion  
Several reviews conclude that overall studies have shown that adjunctive psychotherapy has 
beneficial effects for patients with BD (e.g. Beynon et al., 2009; Miklowitz & Scott, 2009; 
Szentagotai & David, 2010), However, at least when focusing on the studies evaluating CBT it 
is only justified to conclude that adjunctive CBT is mostly more effective than treatment-as-
usual or waiting for treatment. We addressed therefore the question of whether CBT shows any 
evidence for post-treatment benefits and relapse prevention that go beyond those of a supportive 
therapy (ST) equal in number and duration of sessions and including information and a mood 
diary.  
Disregarding any trends, the general picture is that the changes observed over time in both 
CBT and ST in subsyndromal symptoms and cognitive factors such as locus of control were the 
same but that the  treatments did not differ on post-treatment outcome. The same was true for 
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rates of recurrence and time until recurrence. Partially in line with prior studies (e.g. Scott et al., 
2006; Zaretsky et al., 2008) higher risk for any recurrence was predicted by a higher number of 
prior episodes, lower number of therapy sessions and bipolar-II-disorder. The pattern for 
depressive and manic recurrence was different but it is not clear whether this is due to low 
power for distinct episodes or evidence for polarity-specific predictors (e.g. Johnson & Meyer, 
2004).   
Our results contrast with other studies which showed that psychosocial treatments 
significantly reduced relapse rates (e.g. Lam et al., 2003; Miklowitz et al., 2003). However, 
most studies either used a waiting list control group, TAU or fewer sessions (e.g. Zaretsky et al, 
2008). While Colom et al (2003) used an unstructured group setting as a control condition, their 
and our study are not directly comparable; they focused on group treatment while we had an 
individual therapy setting.  Most closely resembling our ST condition, is the ‘intensive clinical 
management’ used by Frank et al. (2005) as a control group in their RCT evaluating IPSRT. 
Initial analyses revealed that it is not the specific kind of treatment per se but the continuity of 
the treatment condition from the acute to the maintenance phase that was beneficial (Frank et 
al., 1999).  
What do our results imply? Time effects do not necessarily reflect treatment effects because 
other factors could contribute to or account for those changes as well. Non-significant 
differences in relapse rates can indicate either a lack of efficacy for both CBT and ST or equal 
effectiveness. The pattern of results – decreases in depression, increases in psychosocial 
functioning, no changes in medication adherence, specific changes in locus of control – 
resemble other studies (e.g. Lam et al., 2003, Scott et al., 2001). Very few other studies included  
such a long follow-up of 2 years in addition to the treatment period, but the overall relapse rate 
of 64.5% for 33 months is still within the range of relapse rated reported by some others (e.g. 
Colom et al., 2003: 66.7% versus 91.7%; Lam et al., 2005: 63.8% versus 84%).  We therefore 
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conclude that the observed effects are unlikely in the absence of any treatment added to 
medication. 
The question remains why CBT and ST actually led to these comparable outcomes? First of 
all, information was incorporated in both conditions and is generally considered essential in all 
psychosocial treatments for BD (Scott et al., 2007; Miklowitz & Scott, 2009). Secondly, the 
mood diary was originally used to increase credibility of our ‘control condition’ and to disguise 
outcome of the randomisation process. However, we believe that the self-monitoring proved to 
be central for many patients and triggered in many patients self-management and self-regulation 
processes regardless of the treatment condition.  
Before drawing final conclusions, some limitations should be considered; Firstly, the sample 
size might be considered small. Although we acknowledge that this study is smaller than others 
(e.g. Lam et al., 2003, 2005; Scott et al., 2006), the sample was larger than needed according to 
our original power analysis. Additionally, the effect size of R2=.001 for treatment effects with 
regard to recurrences, implies that only an enormous sample would potentially find any 
evidence for differential effects or moderators for CBT versus ST. Secondly, we did not 
formally assess adherence to the treatment manuals. We cannot totally rule out that this could 
have affected results, but the training and especially the weekly video-based supervision was 
aimed at reducing risk of deviating from the manuals. Finally, a potential bias in participation 
and drop-out was observed which affects generalizability of the results but is not surprising (e.g. 
McFarland & Klein, 2005; Shea et al., 1990). However, we were less restrictive in our inclusion 
criteria than other studies trying to increase external validity.  
In summary, our study adds to the complex picture that CBT might work better when there is 
nothing else in place (e.g. waiting, TAU), but we did not find much evidence for specific effects 
of CBT for BD. Given that there are several psychological approaches for BD, future research 
should focus on the question of matching patients to treatments. Furthermore, considering 
depression different treatments have been developed so that treatment options now differ for 
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acute depression, for chronic depression or for recurrent depression (e.g. Barton et al., 2008; 
McCullough, 2000; Segal et al., 2002). A similar approach might be needed for improving 
outcomes in patients with bipolar-I or -II disorder or those with different comorbidities.  
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Figure 1: 
 
Flowchart of recruitment of patients 
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     - (hypo)manic: n = 10 
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  - any mood: n = 20 
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 - n = 33 completers 
- n = 5 dropouts 
 - n = 32 completer 
- n = 6 dropouts 
 
   
       
 
 
 
 
 
 
 
 
 
CBT vs ST for BD – 2 years  20 
Table 1:  
Baseline characteristics of patients before treatment (t0) as well as recurrence rates during follow-up  
Treatment condition Cognitive Behavior 
Therapy 
(n = 38) 
Supportive 
Therapy 
(n = 38) 
Statistics 
Gender (% women) 18 (47.4 %) 20 (52.6 %) χ2(1, n = 76) = 0.61, n.s. 
Age (M +/- SD)       44.4 (11.0)  43.5 (12.7) t (74) = 0.32, n.s. 
Age of onset (M +/- SD) 26.6 (9.2) 29.8 (12.4) t (74) = -1.28, n.s. 
Martial status 
– single 
– married 
– divorced 
 
16 (42.1 %) 
15 (39.5 %) 
7  (18.4 %) 
 
16 (41.0 %) 
16 (41.0 %) 
7 (17.9 %) 
 
 
χ
2(2, n = 76) = 0.11, n.s. 
Diagnosis 
- Bipolar I 
- Bipolar II  
 
30 (78.9 %) 
8 (21.1 %) 
 
30 (78.9 %) 
8 (21.1 %) 
 
χ
2(1, n = 76) = 0.00, n.s. 
Comorbid Axis I –Diagnosis 
– Alcohol abuse/- dependency  
– Substance abuse/- dependency 
– Anxiety disorders    
 
8 (21.1 %) 
6 (15.8 %) 
8 (21.1 %) 
 
9 (23.7 %) 
4 (10.5 %) 
10 (26.3 %) 
χ
2(1, n = 76) = 0.08, n.s. 
χ
2(1, n = 76) = 0.46, n.s. 
χ
2(1, n = 76) = 0.29, n.s. 
Personality disorder 7 (18.4 %) 8 (21,1 %) χ2(1, n = 76) = 0.08, n.s. 
Beck Depression-Inventory 13.50 (9.8) 11.03 (7.60) t (74) = 1.29, n.s. 
Hamilton Depression Scale (23) a 9.6 (6.2) 10.2 (6.3) t (74) = -0.41, n.s. 
Self Rating Mania Scale  17.7 (11.0) 19.3 (11.2) t (73) = 0.63, n.s. 
Young Mania Rating Scale 4.0 (5.5) 2.3 (4.6) t (74) = 1.52, n.s. 
Global Assessment Scale 67.4 (12,4) 71.8 (12.6) t (74) = 1.55, n.s.. 
Somatotherapy-Index a 2.7 (1.5) 2.6 (1.3) t (74) = 0.15, n.s.. 
Cognitive functioning b               56.9 (7.2)        59.6 (6.2) t (74) = -1.58, n.s.. 
Recurrence (9 months treatment) 12 (31.6%) 20 (52.6%) χ2(1, n=76)=3.46, p = 0.06 
Recurrence (9 months plus 24  
    months follow-up)  
  
 
     Major depressive episode 19 (50 %) 17 (44.7 %)  
     Any manic episodes 16 (42.1 %) 11 (28.9 %)  
          Hypomanic episode 10 (26.3 %) 5 (13,2 %)  
          Manic episode  10 (26.3 %) 7 (18.4 %)  
          Mixed episode 0 (0,0 %) 1 (1.3 %)  
    Any affective episode 26 (68,4 %) 23 (60.5 %)  
 
a
 Somatotherapy-Index (Mark Bauer et al., Providence, RI, unpublished manuscript)  
b
 Cognitive functioning was assessed with an intelligence test (Leistungsprüfsystem, Horn, 1983) which provide standardized T 
scores (M = 50, SD =10) 
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Table 2:  
Symptoms and indicators of psychosocial functioning pre (t0) and post intervention (t1)  
Outcome  Cognitive Behavior 
Therapy  
Supportive  
Therapy 
Statistics a) 
  N M SD n M SD  
Drop-outs   5   
(13,2 %) 
  6  
(15,8 %) 
  
 
χ
2(1, n = 76) = 0.11 
Beck Depression Inventory t0                                                        
t1 
 13.50
10.93 
9.38
9.17 
 11.03 
6.00 
7.60 
4.35 
T: F = 17.81, p  < .001 
TxI: F = 1.86 
Self Rating Mania Inventory t0                                                        
t1 
 17.65
15.83 
10.98
11.66 
 19.27 
15.18 
11.22 
10.09 
T: F = 7.07, p  < .01 
TxI: F = 1.05 
Bech Rafaelsen Melancholia 
Scale 
t0                                                        
t1 
 6.08
4.29  
4.70
5.08 
 5.55 
3.47 
5.24 
4.53 
T: F = 10.26, p  < .005 
TxI: F = 0.06 
Bech Rafaelsen Mania Scale t0                                                        
t1 
 2.34
1.64 
3.69
3.37 
 1.03 
0.79 
2.56 
1.19 
T: F = 2.14 
TxI: F = 0.53  
Global Assessment Scale  t0                                                        
t1 
 67.37
73.29 
12.43
14.11 
 71.82 
76.32 
12.62 
16.79 
T: F = 8.90, p < .01 
TxI: F = 0.17 
Medication adherence 
(Somatotherapy-Index) b)          
t0                                                        
t1 
 2.55
2.53 
1.59
1.45 
 2.50 
2.53 
1.41 
1.47 
T: F = 0.00 
TxI: F = 0.03 
LC - Internal locus of control t0                                                        
t1 
 26.42
28.13 
7.54
5.15 
 26.24 
28.41 
5.60 
5.59 
T: F = 12.68, p < .011 
TxI: F = 0.17 
LC - External locus of control – 
Powerful others 
t0                             
t1 
 24.24 
24.92 
5.34 
4.88 
 25.59 
25.30 
5.72 
5.36 
T: F = 0.13 
TxI: F = 0.84 
LC - External locus of control – 
Chance 
t0                                                        
t1 
 20.34
18.03 
7.74
7.10 
 22.66 
20.76 
7.29 
7.02 
T: F = 10.29, p < .01 
TxI: F = 0.10 
Trust in medication (KK) t0                                                        
t1 
37 13.14
13.78 
3.77
4.10 
38 13.21 
12.61 
4.05 
4.48 
T: F = 0.00 
TxI: F = 2.63, p = .11 
Trust in psychiatrist (KK) t0                        
t1 
38 9.95 
10.58 
2.78 
3.22 
38 10.05 
9.84 
2.90 
2.39 
T: F = 0.89 
TxI: F = 3.55, p = .06 
Negative expectations (KK) t0                                                        
t1 
38 7.53
6.79 
4.17
3.43 
38 8.00 
7.36 
3.42 
3.31 
T: F = 4.559, p < .05 
TxI: F = 0.02 
Feeling of guilt (KK)  t0                                                        
t1 
38 4.71
5.03 
3.04
2.40 
38 5.34 
4.95 
2.27 
2.48 
T: F = 0.02 
TxI: F = 1.56 
Chance (KK) t0                                                   
t1 
37 7.27
6.92 
3.53
3.70 
38 8.63 
7.63 
3.72 
3.95 
T: F = 3.23, p = .08 
TxI: F = 0.74 
Personal vulnerability (KK) t0                                                        
t1 
38 6.13
6.45 
3.21
3.06 
38 6.11 
6.05 
2.68 
2.85 
T: F = 0.35 
TxI: F = 0.68 
Idiosyncratic assumptions (KK) t0                                                        
t1 
38 6.92
6.21 
3.66
4.02 
37 8.30 
7.62 
3.57 
3.01 
T: F = 4.82, p < .05 
TxI: F = 0.00 
        
 Notes: KK: Krankheitskonzept Skala (Illness Concept scale) Linden et al. and its subscales; LC (Locus of Control) scales.  
a)
 T: F-value for main effect of time, I:  F-value for main effect of treatment condition, IxT: F-value for the interaction term of 
time and treatment condition 
b)
 Somatotherapy-Index: This index is a score varying between 0 and 5 to describe the quality of prescribed and taken 
medication based primarily on blood serum levels (Mark Bauer et al., Providence, RI, unpublished manuscript)  
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Table 3:  
Predictors in the Cox regression models for recurrence of depression, mania and any affective episode 
Variables B (SE) Wald Odds Ratio CI 95 % 
Any affective episode     
Diagnosis -.91 (.37)  6.07* 0.40 0.20 – 0.83 
Medication adherence .04 (.11) 0.00 1.00 0.81 – 1.25 
Age of onset .20 (.01) 2.13 1.02 0.99 – 1.05 
Psychosocial functioning (GAS t0) -.01 (.01) 0.39   0.99 0.97 – 1.02 
Number of episodes .57 (.25)  5.27* 1.77 1.09 – 2.87 
Number of episodes x time -.16 (.01)    6.77** 0.98 0.97 – 1.00 
Number of therapy sessions -.11 (.04)  6.45* 0.90 0.83 – 0.98 
Treatment condition .10 (.30) 0.11 1.10 0.61 – 1.96 
Recurrence of depression     
Diagnosis    -1.05 (.41)     6.65** 0.35 0.16 – 0.78 
Medication adherence -.07 (.12) 0.30 0.94 0.73 – 1.19 
Age of onset .03 (.02)   3.81‡ 1.03 1.00 – 1.06 
Psychosocial functioning (GAS t0) -.02 (.02) 1.16 0.98 0.96 – 1.01 
Number of episodes .47 (.29)  2.70 1.60 0.91 – 2.81 
Number of episodes x time -.02 (.01)  4.70* 0.98 0.07 – 1.00 
Number of therapy sessions -.11 (.05)  4.95* 0.90 0.81 – 0.98 
Treatment condition -.01 (.01) 0.00 0.99 0.97 – 1.00 
Recurrence of mania     
Diagnosis -.60 (.48) 1.57 0.55 0.21 – 1.40 
Medication adherence -.06 (.15) 0.19 0.94 0.71 – 1.25 
Age of onset -.02 (.02) 0.82 0.98 0.95 – 1.02 
Psychosocial functioning (GAS t0) .00 (.02) 0.03 1.00 0.97 – 1.04 
Number of episodes .71 (.32)  4.95* 2.04 1.09 – 3.81 
Number of episodes x time -.01 (.01) 2.36 0.99 0.98 – 1.00 
Number of therapy sessions -.07 (.08) 0.96 0.93 0.80 – 1.08 
Treatment condition .51 (.40) 1.62 1.66 0.98 – 1.00 
Notes: Diagnosis coded ‘1’ as Bipolar I and ‘2’ as Bipolar II; Number of prior episodes – logarithmically 
transformed (Ln), Medication adherence – scores according to Somatotherapy index, 0 = no medication, and 4 = 
optimal level of medication; treatment condition coded as ‘0’ Supportive Therapy, ‘1’ Cognitive Behavior Therapy’  
 ‡ p < .10  
 * p < .05 
** p < .01 
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Figure 2: 
 
Cumulative survival functions with regard to recurrence of any affective episode for Cognitive 
Behaviour Therapy and Supportive Therapy 
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